Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Regeneron Pharmaceutials, Inc.

1 abstract

Abstract
A phase 1 study of REGN6569, a GITR mAb, in combination with cemiplimab in patients (pts) with advanced solid tumor malignancies: Initial dose-escalation results.
Org: Institut Català d’Oncologia-IDIBELL, Regeneron Pharmaceutials, Inc.,